Diligence memo · auto-generated · as of July 2, 2026

VytronUS Inc

VytronUS Inc looks fair against its niche peers and is dormant on financing cadence.

DeprioritizeFinancing has gone silent well past the sector's normal cadence — treat as inactive until outside confirmation of a live operation.

Businessfiled

VytronUS Inc operates in Other Health Care, based in SUNNYVALE.

No verified homepage on file yet — operating evidence is limited to the public record.

Capital & rounds (filed)filed

VytronUS Inc has raised $91M in disclosed capital across 6 recorded rounds, aggregated from public filings. Its latest round is modeled as Series B (a $15M–$40M round).

Largest single filing: $30M on 2016-07-14.

Most recent recorded round closed around 2016-07-14.

Valuation (modeled)modeled

Provath models VytronUS Inc at approximately $665M (range $71M–$2.6B). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.

Read: Fair. Modeled value is 1.48× the median modeled value of Series B Other Health Care companies in 2016–2018 (74 peers) — value vs value, same stage and era. Within the normal band (148% of peer median) for its niche.

Financing rhythm & timingmixed

Historic cadence: a new round about every 17 months.

Last raise 10.0 yr ago; this sector typically re-raises about every 14 months.

Silent for over 3× the sector's normal cadence.

The last round was 1.1× smaller than the prior — a bridge or down round.

Comparablesmixed

Capital scale ranks ahead of 95% of Other Health Care peers (5377 compared).

Modeled value ranks above 95% of those peers.

Closest niche peers: Podicare Services, Inc., COTA, Inc., Fresenius Medical Care - Meridian Health System, LLC, Headspace, Inc., Spine Holdings LLC.

Peoplefiled

18 named people on file across officers, directors and signatories.

Risks & flagsmixed

Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.

No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.